Total Payments
$4,922
2024 Payments
$570.15
Companies
51
Transactions
244
Medicare Patients
2,145
Medicare Billing
$204,319
Payment Breakdown by Category
Food & Beverage$4,367 (88.7%)
Education$554.82 (11.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,367 | 233 | 88.7% |
| Education | $554.82 | 11 | 11.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $575.56 | 18 | $0 (2024) |
| PFIZER INC. | $402.72 | 21 | $0 (2024) |
| Astellas Pharma US Inc | $349.08 | 11 | $0 (2020) |
| Merck Sharp & Dohme LLC | $296.68 | 18 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $276.31 | 21 | $0 (2020) |
| Amgen Inc. | $231.86 | 15 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $226.94 | 12 | $0 (2024) |
| Janssen Biotech, Inc. | $220.49 | 9 | $0 (2024) |
| Celgene Corporation | $193.44 | 10 | $0 (2020) |
| GENZYME CORPORATION | $172.43 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $570.15 | 19 | Lilly USA, LLC ($104.76) |
| 2023 | $205.68 | 2 | ABIOMED ($120.51) |
| 2022 | $223.56 | 8 | Lilly USA, LLC ($86.14) |
| 2021 | $378.70 | 15 | GENZYME CORPORATION ($110.26) |
| 2020 | $459.46 | 30 | Celgene Corporation ($42.27) |
| 2019 | $1,798 | 107 | Janssen Biotech, Inc. ($202.67) |
| 2018 | $1,262 | 62 | PFIZER INC. ($161.26) |
| 2017 | $24.11 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($24.11) |
All Payment Transactions
244 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $36.03 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.95 | General |
| Category: Hematology/Oncology | ||||||
| 12/05/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $33.27 | General |
| Category: Oncology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $33.86 | General |
| Category: Oncology | ||||||
| 11/20/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $22.47 | General |
| 11/15/2024 | Lilly USA, LLC | VERZENIO (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $23.32 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $21.29 | General |
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $19.25 | General |
| 11/07/2024 | Genentech USA, Inc. | Itovebi (Biological), Tecentriq, Tecentriq Hybreza | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: BioOncology | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $30.71 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $15.65 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $31.56 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $67.51 | General |
| 01/31/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $80.26 | General |
| Category: Diabetes | ||||||
| 12/14/2023 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $120.51 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/19/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Food and Beverage | In-kind items and services | $85.17 | General |
| Category: Oncology | ||||||
| 09/14/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $86.14 | General |
| Category: Diabetes | ||||||
| 09/12/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX, PAXLOVID | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2022 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: HEMATOLOGY | ||||||
| 04/25/2022 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 178 | 334 | $29,946 | $8,769 |
| 2022 | 18 | 791 | 3,043 | $204,918 | $80,867 |
| 2021 | 32 | 1,015 | 21,586 | $321,558 | $103,205 |
| 2020 | 8 | 161 | 221 | $26,042 | $11,478 |
Total Patients
2,145
Total Services
25,184
Medicare Billing
$204,319
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 14 | 33 | $11,715 | $2,787 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 20 | $3,240 | $1,634 | 50.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 35 | $3,640 | $1,548 | 42.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 69 | $6,210 | $1,381 | 22.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 52 | 92 | $1,656 | $772.80 | 46.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 50 | 85 | $3,485 | $646.85 | 18.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 86 | 153 | $24,786 | $14,708 | 59.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 19 | 127 | $45,085 | $13,455 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 76 | $17,860 | $10,549 | 59.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 90 | 134 | $13,936 | $9,095 | 65.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 23 | 265 | $23,850 | $6,155 | 25.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 69 | 69 | $10,350 | $5,691 | 55.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 52 | $8,320 | $4,246 | 51.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 141 | 465 | $19,065 | $3,543 | 18.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 21 | 21 | $7,140 | $3,145 | 44.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $6,360 | $2,935 | 46.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 28 | 28 | $5,068 | $2,240 | 44.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 21 | 35 | $5,600 | $1,678 | 30.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 145 | 526 | $9,468 | $1,549 | 16.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 11 | 45 | $3,600 | $1,023 | 28.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 15 | 48 | $2,016 | $490.50 | 24.3% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2022 | 21 | 38 | $1,330 | $234.56 | 17.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 17 | 888 | $888.00 | $85.27 | 9.6% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 14 | 49 | $196.00 | $45.00 | 23.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 19 | 85 | $13,600 | $13,626 | 100.2% |
About Dr. Sameer Baig, MD
Dr. Sameer Baig, MD is a Hematology & Oncology healthcare provider based in Connelly Springs, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/16/2014. The National Provider Identifier (NPI) number assigned to this provider is 1093129207.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sameer Baig, MD has received a total of $4,922 in payments from pharmaceutical and medical device companies, with $570.15 received in 2024. These payments were reported across 244 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($4,367).
As a Medicare-enrolled provider, Baig has provided services to 2,145 Medicare beneficiaries, totaling 25,184 services with total Medicare billing of $204,319. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Connelly Springs, NC
- Active Since 06/16/2014
- Last Updated 03/04/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093129207
Products in Payments
- KEYTRUDA (Biological) $242.05
- OPDIVO (Biological) $226.53
- IMBRUVICA (Drug) $213.16
- MOUNJARO (Drug) $166.40
- Impella (Device) $120.51
- XTANDI (Drug) $117.44
- LIBTAYO (Biological) $110.26
- SOLIRIS (Drug) $93.98
- XELJANZ (Drug) $91.31
- Revlimid (Drug) $87.49
- Abraxane (Drug) $85.35
- Tazverik (Drug) $85.17
- XALKORI (Drug) $84.99
- CYRAMZA (Drug) $81.86
- XOSPATA (Drug) $78.64
- ALIMTA (Drug) $69.61
- IBRANCE (Drug) $69.30
- IMFINZI (Biological) $67.13
- LYNPARZA (Drug) $66.87
- COSELA (Drug) $63.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.